394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

Bibliographic Details
Main Authors: Ignacio Melero, Diwakar Davar, Emiliano Calvo, Donald Richards, Sarina Piha-Paul, Matthew Dallos, Martin Gutierrez, Matteo Simonelli, Jason Melear, Janaki Parameswaran, Vinit Kumar, Xiaochen Zhao, Santanu Dutta
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items